Background {#Sec1}
==========

The complexity of human disease biology presents many challenges for the development and approval of new medicines. It is very difficult to design drug molecules with activity specific for a single biological pathway unique to diseased cells; with a pharmacokinetic profile with optimal onset and/or duration of action; or without detrimental side effects due to systemic exposure. In addition, patient compliance in taking medicines can offer significant challenges. Drug delivery systems offer the possibility to design and engineer levels of control beyond the drug molecule's inherent properties to overcome the aforementioned challenges.

Pioneering drug delivery with biodegradable PLGA microparticles {#Sec2}
===============================================================

Until the mid-1970s, many thought that controlled release drug delivery was limited to small molecules. Pioneering research by Folkman and Langer led the way for sustained release of proteins and other macromolecules \[[@CR1]\]. Biodegradable polymers such as the poly(lactide-*co*-glycolide) (PLG) family degrade by hydrolysis in the body and can be engineered to encapsulate drug molecules in microspheres suitable for subcutaneous or intramuscular injection. Modification of polymer molecular weight or composition, drug loading levels, and particle size can be utilized to tune the rate of polymer and microsphere degradation and corresponding drug release profiles. Leuprorelin, or leuprolide, is a gonadotropin-releasing hormone that was initially approved to treat prostate cancer in 1985 in an unencapsulated form and required daily injections due to its inherent pharmacokinetic profile. In 1989, Lupron Depot®, a PLG microsphere with encapsulated leuprolide acetate, was initially approved for the treatment of prostate cancer as a once-monthly intramuscular injection. This dramatic reduction in the frequency of injections led the way for many additional PLG microsphere-based medicines. Although not a long-term commercial success, in 1999, Nutropin Depot® was approved by the FDA for the treatment of growth failure due to a lack of adequate endogenous growth hormone secretion. This product comprised 22-kD recombinant human growth hormone encapsulated in a PLG microsphere which permitted dosing once or twice a month, as opposed to the typical daily subcutaneous injection dosing regimen \[[@CR2]\]. A much larger success for a PLG microsphere product is Risperdal Consta®. Risperidone is an anti-psychotic medicine used to treat schizophrenia and bipolar disorder. Administered as a daily oral medication, patient compliance is critically important as missed doses can lead to relapse and increased psychotic symptoms. In 2003, the FDA approved Risperdal Consta®, a controlled release form of risperidone encapsulated in PLG microspheres that enabled dosing once every 2 weeks by intramuscular injection. Compared with the parent oral risperidone, less frequent dosing and improved compliance with administration by a health care professional rather than patient self-administration has made Risperdal Consta® a major success for treating these brain disorders \[[@CR3]\].

Advancing drug delivery with nanoparticles {#Sec3}
==========================================

The many successes of controlled release microsphere-based medicines led innovators to explore the potential of drug delivery for systemic administration to reach specific sites of disease, with particular interest in targeting tumors for treating cancer. This cannot be achieved with microspheres, because they would be rapidly cleared from plasma. As a result, research efforts shifted toward reducing particle sizes (diameters [\<]{.ul} 100 nm) and surface modification using poly(ethylene glycol) to avoid immune recognition and clearance. Seminal papers in the field of nanomedicine were published in the early 1990s on PEGylated liposomes \[[@CR4]\] and polymeric nanoparticles \[[@CR5]\]. These efforts built upon the pioneering research by Maeda and Matsumura in the mid-1980s which demonstrated enhanced permeability and retention of macromolecules based upon their size owing to tumor leaky vasculature and poor lymphatic drainage \[[@CR6]\].

The first FDA-approved cancer nanomedicine was Doxil®, a PEGylated liposome containing doxorubicin. It was initially approved in 1995 for the treatment of AIDS-related Kaposi's sarcoma, and subsequently for treating ovarian cancer and multiple myeloma (in combination with bortezomib). Doxil increased doxorubicin circulation half-life by approximately 4-fold and tumor drug levels up to 10-fold in preclinical models \[[@CR4]\]. By containing doxorubicin within the liposome and targeting more drug to tumor, Doxil also showed an improved toxicity profile in patients, by greatly reducing the cardiovascular side effects of free doxorubicin \[[@CR7]\].

Ten years after the initial approval of Doxil, a new nanoparticle-based cancer drug received its first approval. In 2005, Abraxane®, a nanoparticle albumin-bound paclitaxel, was initially approved for treating breast cancer. It has also been approved for treating non-small cell lung and pancreatic cancers. Due to its poor solubility, paclitaxel (Taxol®) was originally developed by being dissolved in cremophor EL, a polyoxyethylated castor oil, which can lead to severe anaphylactic or hypersensitivity reactions. By solubilizing paclitaxel in albumin nanoparticles, Abraxane eliminated the need for cremophor and improved the tolerability profile of paclitaxel, with the highest label recommendation for Taxol at 175 mg/m^2^, whereas Abraxane can be dosed as high as 260 mg/m^2^ \[[@CR8]\].

Enabling true therapeutic innovation with nanoparticles {#Sec4}
=======================================================

The first two waves of drug delivery enabled products with enhanced utility, compliance, and therapeutic window relative to the existing therapeutic agent. Current drug delivery innovations feature ambitious efforts to deliver large macromolecules to specific disease locations on timelines generally thought impossible. The developments of many of today's most innovative therapeutics are utilizing nanoparticle drug delivery systems, and for our scope, we will focus on RNA nanomedicines.

In 1998, Fire and Mello started a new revolution for gene therapy and gene editing, beginning with the statement, "Experimental introduction of RNA into cells can be used in certain biological systems to interfere with the function of an endogenous gene" \[[@CR9]\]. Significant research has gone into developing short interfering RNA (siRNA) for RNA interference to turn off destructive biological pathways. Unmodified RNAs require drug delivery systems as they are not stable in biological fluids and do not readily penetrate into target cells where their action is required to reprogram the production of proteins. Building off the success of Doxil and other liposomal or lipid nanoparticles, major efforts focused on the optimization of lipid nanoparticles for the delivery of RNA \[[@CR10]\].

Twenty years later in 2018, the first siRNA product was approved in 2018. Onpattro® (Patisiran) is a lipid nanoparticle containing siRNA to stop the toxic production of transthyretin in patients with polyneuropathies induced by hereditary transthyretin amyloidosis \[[@CR11]\].

A second RNA wave has focused on developing messenger RNA (mRNA) therapies to promote healthy protein expression to treat diseases. A major potential advantage of mRNA therapies is the possibility to treat patients regardless of any particular genetic mutation. For cystic fibrosis, mutations in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) gene can impact CFTR protein folding and capability to regulate salt transport. The most debilitating impact of CF and primary cause of mortality is the inability to clear mucus from the lungs, causing build-up and decreased lung function. Multiple programs, one of which is in early clinical development \[[@CR12]\], are focused on inhaled mRNA to encode normal CFTR protein to restore healthy lung function. These approaches entail encapsulation of mRNA in lipid nanoparticles which are then inhaled as nebulized solutions to allow delivery to the upper airways where CFTR protein is produced.

In addition to therapeutic treatments, mRNA vaccines offer a promising opportunity due to their high potency, capacity for rapid development, and safe administration \[[@CR13]\]. These potential advantages for mRNA vaccines are currently being played out in real time, as the Covid-19 pandemic is driving innovation and implementation in an effort to rapidly develop an mRNA vaccine. Several academic and industry groups around the world are putting a huge effort into developing therapeutics and vaccines for Covid-19. One company whose efforts merit highlighting at this point is Moderna. On January 11, 2020, the Chinese authorities shared the genetic sequence of the novel coronavirus. On January 13, 2020, the NIH Vaccine Research Center and Moderna's infectious disease research team finalized the sequence for the SARS-CoV-2 vaccine and Moderna mobilized toward clinical manufacture. The first clinical batch was completed on February 7, 2020, and underwent analytical testing; it was shipped on February 24, 2020, from Moderna and delivered to NIH from the Company's manufacturing facility in 42 days from sequence selection. The first participant in an NIH-led phase 1 clinical study was dosed on March 16, 2020 \[[@CR14]\]. Such a timeline from virus sequencing to human dosing has never been achieved and was likely never thought possible. A critical enabling element to this impressive achievement was the development of a robust lipid nanoparticle delivery platform with the capability to be applied across mRNA sequences for developing vaccines as well as therapeutic mRNA modalities \[[@CR15], [@CR16]\].

Conclusion {#Sec5}
==========

From rather modest beginnings, drug delivery technologies are now enabling a vast landscape of new and innovative therapies. From academic labs to large biopharmaceutical companies, the collaboration between scientists, engineers, and clinicians will continue to advance therapies with drug delivery systems to address ongoing unmet patient needs. Over the past 50 years, we have witnessed an incredible evolution in drug delivery. Earlier generations featured improved versions of existing drugs utilizing controlled release microspheres and long-circulating nanoparticles for cancer treatments. Today, innovative nanotechnologies are core to the development of novel medicines to treat a range of serious diseases.
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